What are the applications of Flt3 receptor interacting lectin FRIL? 

The Flt3 receptor-interacting lectin (FRIL), extracted from plants such as Dolichos Lablab, has shown significant potential in various biomedical applications, particularly in the field of stem cell research and cancer therapy. One of the primary applications of FRIL is in the ex vivo maintenance of stem cells. Studies have demonstrated that FRIL can preserve hematopoietic stem cells (HSCs) in vitro by maintaining them in a quiescent state, thereby inhibiting both cell proliferation and differentiation. This effect is crucial for many clinical applications, including stem cell transplantation and gene therapy, as it allows for the extended manipulation and expansion of stem cells without losing their primitive characteristics . FRIL achieves this by down-regulating cell cycle regulators such as cyclin D3 and CDK6, and activating P53, which are involved in the G0/G1 phase regulation, thus preserving the self-renewal property of HSCs/HPCs by halting their cell cycles . Additionally, FRIL's interaction with novel hematopoietic cell cycle regulators, HTm4 and HTm4S, plays a crucial role in maintaining the quiescence of human cord blood stem cells, further highlighting its potential for clinical applications . Beyond stem cell preservation, FRIL has implications in cancer therapy. The FLT3 gene, which FRIL interacts with, is implicated in the development of acute myeloid leukemia (AML). Research has shown that T cells modified with a chimeric antigen receptor that includes an FLT3 binding domain can specifically target and kill leukemia cells expressing FLT3, suggesting that FRIL or its mechanisms could be harnessed for targeted cancer immunotherapy . Moreover, the use of FRIL in conjunction with RNA vaccines to enhance immune responses against cancer cells is being explored, indicating its potential role in vaccine delivery and immunotherapy . In summary, FRIL's applications span from stem cell preservation, offering a novel approach to maintain stem cells in a quiescent state for extended periods, to targeted cancer therapy, where its interaction with FLT3 could be leveraged for designing more effective treatments against FLT3+ leukemia and potentially other cancers .

cDNA cloning of FRIL, a lectin from Dolichos lablab, that preserves hematopoietic progenitors in suspension culture

FRIL, a lectin interacting with the Flt3 receptor, preserves hematopoietic progenitors without cytokines, potentially aiding in stem cell transplantation, leukemia treatment, and gene therapy applications.

Utilisation d'un ligand de flt3 pour le renforcement de réactions immunitaires lors de l'immunisation arn

Not addressed in the paper.

Extraction, Purification and Function Analysis of a New Lectin Which Can Maintain The Multipotential of Hematopoietic Stem/progenitor Cells In vitro

FRIL, a lectin from lablab, maintains hematopoietic stem/progenitor cells' multipotential in vitro by halting cell cycles, enhancing colony formation, and promoting self-renewal, showing potential in stem cell research.

The mechanisms of a new plant lectin FRIL from dolichos lablab that preserves quiescent hematopoietic stem cells in suspension culture

FRIL from Dolichos lablab preserves quiescent hematopoietic stem cells in suspension culture, indicating its potential application in stem cell research and biotechnology.

[The maintenance of cord blood CD34+ progenitor cells with plant lectin FRIL in vitro and the expression of related cell cycle modulator HTm4 and HTm4S].

FRIL can maintain quiescent primitive CD34(+) cells in vitro without cytokines, potentially extending ex vivo manipulation of human stem cells for clinical applications by preserving progenitor cells.

FLT3 chimeric antigen receptor and application thereof

Not addressed in the paper.

FRIL maintains quiescence of hematopoietic stem cells through regulation of cell cycle related factors

FRIL maintains hematopoietic stem cell quiescence by regulating cell cycle factors like cyclin D3, CDK6, P27, and P53, aiding in stem cell preservation and differentiation.

cDNA cloning of FRIL, a lectin fro hematopoietic progenitors in susp

FRIL, a lectin interacting with the Flt3 receptor, shows potential as a stem cell preservation factor, maintaining primitive hematopoietic progenitors in suspension culture for extended periods without inducing differentiation.

Non‐coding FLT3 Mutation is Associated with Lower Galectin Levels in Breast Cancer Patients

Not addressed in the paper.

Legume lectin FRIL preserves neural progenitor cells in suspension culture in vitro.

FRIL preserves neural progenitor cells in vitro by inhibiting proliferation and differentiation, potentially extending applications to neural stem cell transplantation and treatment of neural degenerative diseases.